Exome Asset Management »

4d Molecular Therapeutics In shares owned by Exome Asset Management

Quarter-by-quarter ownership of 4d Molecular Therapeutics In (FDMT) shares owned by Exome Asset Management from 13F filings

Historical chart of Exome Asset Management investment in 4d Molecular Therapeutics In

Tip: Access up to 7 years of quarterly data

All positions including 4d Molecular Therapeutics In held by Exome Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in 4d Molecular Therapeutics In by Exome Asset Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $1.2M 131k 9.31

More positions owned by Exome Asset Management

Praxis Precision Medicines I Com New (PRAX)
Cogent Biosciences (COGT)
Enliven Therapeutics (ELVN)
Ionis Pharmaceuticals (IONS)
Spdr Series Trust State Street Spd Put Option (XBI)
Guardant Health (GH)
Cytokinetics Com New (CYTK)
Eli Lilly & Co. (LLY)
Alumis (ALMS)
Bridgebio Pharma (BBIO)
Vera Therapeutics Cl A (VERA)
Insmed Com Par $.01 (INSM)
Anthem (ELV)
Agios Pharmaceuticals (AGIO)
United Therapeutics Corporation (UTHR)

View all positions for Exome Asset Management

Top funds holding 4d Molecular Therapeutics In

Henderson Group
RA Capital Management
Goldman Sachs Group
BlackRock
Novo A/S
BVF
State Street Corporation
Armistice Capital
Adage Capital Partners GP
Federated Investors
Trails Edge Capital Partners
Geode Capital Management
Bank of America Corporation
Evergreen Quality Fund GP
Deutsche Bank Aktiengesellschaft

View all funds holding 4d Molecular Therapeutics In